Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 3 1Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasm Metastasis 3Colorectal Neoplasms 3Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Pancreatic Neoplasms 1Lung Neoplasms 1Colonic Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Oxaliplatin 16Irinotecan 12Fluorouracil 12Leucovorin 10Bevacizumab 8pembrolizumab 7Cetuximab 7Capecitabine 7Nivolumab 5Gemcitabine 5Cyclophosphamide 5fludarabine 4aldesleukin 4Panitumumab 4Folfox protocol 4oblimersen 3Interleukin-2 3selpercatinib 2poly ICLC 2labetuzumab 2dehydroftorafur 2conatumumab 2cemiplimab 2bintrafusp alfa protein, human 2Tomography, X-Ray Computed 2Specimen Handling 2Receptor Protein-Tyrosine Kinases 2Radiotherapy 2Levoleucovorin 2Injections 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Colonic Neoplasms × adagrasib × Clear all
NCT03785249 2025-09-30

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

Mirati Therapeutics Inc.

Phase 1/2 Active not recruiting
731 enrolled 1 FDA
Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡